Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | CCR1 | P32246 | 5/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536946 | 1.00 | CNR1 (0.49) | CNR1CNR2CCR1PRKCZPDE5A | |
| SCHEMBL2537293 | 1.00 | CNR1 (0.49) | CNR1CNR2CCR1PRKCZPDE5A | |
| SCHEMBL2540628 | 0.93 | CNR1 (0.50) | CNR1CNR2CCR1PRKCZPDE5A | |
| SCHEMBL2541604 | 0.93 | CNR1 (0.44) | CNR1CNR2CCR1PDE5AGAA | |
| SCHEMBL2537481 | 0.91 | CNR1 (0.43) | CNR1CNR2CCR1HTTALDH1A1 | |
| SCHEMBL2537767 | 0.90 | CNR1 (0.48) | CNR1CNR2PDE5AGAAHTT | |
| SCHEMBL2538222 | 0.90 | CNR1 (0.48) | CNR1CNR2PDE5AGAAHTT | |
| SCHEMBL2537771 | 0.90 | CNR1 (0.48) | CNR1CNR2PDE5AGAAHTT | |
| SCHEMBL2536570 | 0.89 | CNR1 (0.47) | CNR1CNR2PDE5AALDH1A1MAPT | |
| SCHEMBL2538945 | 0.89 | CNR1 (0.49) | CNR1CNR2PDE5AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | claimed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885CCR1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.